Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis by Thibaut, Hendrik Jan et al.
Binding of Glutathione to Enterovirus Capsids Is Essential
for Virion Morphogenesis
Hendrik Jan Thibaut1,2, Lonneke van der Linden1,3., Ping Jiang4., Bert Thys5, Marı´a-Dolores Canela6,
Leire Aguado6, Bart Rombaut5{, Eckard Wimmer4, Aniko Paul4, Marı´a-Jesu´s Pe´rez-Pe´rez6,
Frank J. M. van Kuppeveld2,3", Johan Neyts1"*
1Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium, 2Virology Division, Department of Infectious
Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands, 3Department Medical Microbiology, Radboud University
Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands, 4Department of Molecular Genetics and Microbiology, School of
Medicine, Stony Brook University, Stony Brook, New York, United States of America, 5Department of Pharmaceutical Biotechnology & Molecular Biology, Vrije Universiteit
Brussel, Brussel, Belgium, 6 Instituto de Quı´mica Me´dica (IQM-CSIC), Madrid, Spain
Abstract
Enteroviruses (family of the Picornaviridae) cover a large group of medically important human pathogens for which no
antiviral treatment is approved. Although these viruses have been extensively studied, some aspects of the viral life cycle, in
particular morphogenesis, are yet poorly understood. We report the discovery of TP219 as a novel inhibitor of the
replication of several enteroviruses, including coxsackievirus and poliovirus. We show that TP219 binds directly glutathione
(GSH), thereby rapidly depleting intracellular GSH levels and that this interferes with virus morphogenesis without affecting
viral RNA replication. The inhibitory effect on assembly was shown not to depend on an altered reducing environment.
Using TP219, we show that GSH is an essential stabilizing cofactor during the transition of protomeric particles into
pentameric particles. Sequential passaging of coxsackievirus B3 in the presence of low GSH-levels selected for GSH-
independent mutants that harbored a surface-exposed methionine in VP1 at the interface between two protomers. In line
with this observation, enteroviruses that already contained this surface-exposed methionine, such as EV71, did not rely on
GSH for virus morphogenesis. Biochemical and microscopical analysis provided strong evidence for a direct interaction
between GSH and wildtype VP1 and a role for this interaction in localizing assembly intermediates to replication sites.
Consistently, the interaction between GSH and mutant VP1 was abolished resulting in a relocalization of the assembly
intermediates to replication sites independent from GSH. This study thus reveals GSH as a novel stabilizing host factor
essential for the production of infectious enterovirus progeny and provides new insights into the poorly understood
process of morphogenesis.
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Introduction
Enteroviruses, belonging to the family of the Picornaviridae, are
non-enveloped, icosahedral viruses with a positive, single-stranded
genome. Enteroviruses comprise many important pathogens of
humans and animals. Although most enterovirus infections subside
asymptomatically or mildly, they can also result in severe morbidity
and even mortality. Polioviruses cause paralytic poliomyelitis;
rhinovirus infections are associated with exacerbations of asthma
and chronic obstructive pulmonary disease and enterovirus 71 may
cause life-threatening encephalitis, in particular in Asia. Also
coxsackieviruses and echoviruses have been reported to cause acute
clinical manifestations, including fulminant sepsis, aseptic
meningitis and myocarditis [1]. Epidemiological studies strongly
suggest a linkage between coxsackieviruses and the development of
type 1 diabetes mellitus [2]. Apart from polio, no vaccines are
available that can protect against enteroviral infections. No drugs
have been approved so far for the treatment or prophylaxis of
enterovirus infections [3].
The RNA genome of enteroviruses encodes four structural
(VP1, VP2, VP3 and VP4) and seven nonstructural proteins (2A,
2B, 2C, 3A, 3B, 3C and 3D). Following receptor-mediated binding
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to the cell surface, the capsid is destabilized and the viral genome is
delivered into the cytoplasm [4,5]. Genomic RNA is then
translated into a viral polyprotein which is processed into the
structural capsid proteins and the non-structural proteins that are
involved in the replication and production of new positive-strand
RNAs via a negative-strand RNA intermediate. These newly
synthesized positive-strand RNAs are produced on replication
vesicles derived from the Golgi complex and trans-Golgi network
(TGN) and either enter a new round of translation/replication or
are packaged into capsid proteins to yield new infectious virus
particles [6,7].
Despite the fact that morphogenesis represents an important
stage at the end of the virus replication cycle, many aspects of the
molecular mechanisms dictating the assembly of viral particles
remain obscure. It is known that this process occurs in a multi-
tiered manner. In a first step, the capsid precursor P1, consisting
of four structural components VP1 to VP4, is released from the
P2–P3 polyprotein by a cis-cleavage, carried out by 2Apro [8].
Studies with geldanamycin, a specific inhibitor of the cellular
protein chaperone, heat shock protein 90 (Hsp90), have shown
that by interacting with Hsp90, the nascent P1 is maintained in a
processing-competent conformation and is protected from
proteasomal degradation [9,10]. This interaction with Hsp90
(and possibly Hsp70 and several cofactors), allows the precursor
polyprotein P1 to be processed by 3CDpro thereby yielding an
immature structural unit, the protomer particle, containing one
copy of VP0 (consisting of VP4 and VP2), VP3 and VP1 [11,12].
Five of these protomers will then self-oligomerize into a
pentameric particle. This self-assembly has been shown to be
dependent on the modification of an N-terminal glycine residue
of VP0 with myristate, stabilizing interactions at the fivefold axis
between protomers forming pentameric subunits [13–16]. Fur-
ther assembly of twelve pentameric subunits can generate a next
higher-order particle, the empty capsid. It has been long a subject
of debate whether newly synthesized progeny RNA is inserted
into these preformed empty capsids or whether pentameric
particles associate around an active replicating viral genome. An
essential insight into this mechanism was provided by several
studies suggesting a role for the non-structural protein 2C during
encapsidation [17,18]. Evidence was provided that viral en-
capsidation is coupled to genomic RNA synthesis resulting from a
direct interaction between the RNA replication machinery and
capsid proteins, possibly pentameric particles [19]. This hypoth-
esis was extended by a recent study in which genetic and
biochemical evidence was provided that newly synthesized
positive-stranded genomes were encapsidated without an appar-
ent involvement of an RNA packaging signal [20]. More
specifically, a direct protein-protein interaction between 2C, as
an essential component of the replication complex, and capsid
protein VP3, possibly as part of a pentameric particle, was
demonstrated. In this way pentameric particles will only condense
at the site of replication around newly synthesized RNA genomes
[19–21]. Further evidence for an interaction of protein 2C with
capsid proteins during encapsidation was recently provided by a
charged-to-alanine-scanning mutagenesis approach within pro-
tein 2C resulting in encapsidation-defective poliovirus and the
identification of compensatory mutations in VP1 and VP3 [22].
In a last step and concomitantly with the encapsidation of
genomic RNA, VP0 is processed into VP2 and VP4, probably by
an RNA-dependent autocatalytic process, eventually yielding
infectious virions [23].
Several studies provided evidence for a critical role of
glutathione (GSH) during enterovirus morphogenesis [24,25].
GSH is the most prevalent non-protein thiol in the animal cell and
is involved in a multitude of cellular processes, including
maintaining the cellular redox potential and detoxification of
xenobiotics [where GSH serves as a cofactor in conjugation
reactions catalyzed by glutathione peroxidases (GPx) and gluta-
thione-S-transferases (GST)] [26,27]. In addition, GSH has been
shown to play a role in signal transduction, gene expression, cell
proliferation and apoptosis by either maintaining a favorable
redox status of the cell or by directly interacting with cysteine
residues in polypeptidic chains [27]. An imbalance in GSH has
been observed in various pathologies, including cancer, neurode-
generative disorders, cystic fibrosis and aging [28]. Through drug
inhibition studies using buthionine sulfoximine (BSO), a known
irreversible inhibitor of the c-glutamylcysteine synthetase, (a key
enzyme in the glutathione biosynthesis pathway), it was shown that
GSH depletion results in a complete inhibition of the formation of
infectious enterovirus progeny without affecting viral RNA and
protein synthesis [24,25]. The observed dependence on GSH
during enterovirus morphogenesis was most likely not by affecting
favorable cellular redox conditions since addition of other
reducing agents could not substitute for GSH. The exact
mechanism by which GSH is implicated in the formation of virus
progeny remains obscure to date.
In this study, we describe the identification of TP219, a novel
inhibitor of the assembly of several enteroviruses that acts by
scavenging free GSH. By employing this inhibitor, we provide
evidence that a direct interaction between VP1 and GSH is
essential for the transition into or the stabilization of pentameric
particles before assembling into higher-order particles. Further-
more, genetic analysis of coxsackievirus B3 (CVB3) escape mutants
from GSH requirement demonstrated the relevance of a surface-
exposed methionine at the interface of two protomers that may
serve as a surrogate for GSH. Structural analysis of several
naturally GSH-independent enteroviruses provided further evi-
dence for the importance of this single residue in assembly. A role
for GSH as a host factor during enterovirus morphogenesis is
discussed.
Author Summary
Enteroviruses contain many significant human pathogens,
including poliovirus, enterovirus 71, coxsackieviruses and
rhinoviruses. Most enterovirus infections subside mild or
asymptomatically, but may also result in severe morbidity
and mortality. Here, we report on the mechanism of
antiviral action of a small molecule, TP219, as an inhibitor
of enterovirus morphogenesis. Morphogenesis represents
an important stage at the end of the virus replication cycle
and requires multiple steps, of which some are only poorly
understood. Better understanding of this process holds
much potential to facilitate the development of new
therapies to combat enterovirus infections. We demon-
strate that TP219 rapidly depletes intracellular glutathione
(GSH) by covalently binding free GSH resulting in the
inhibition of virus morphogenesis without affecting viral
RNA replication. We discovered that GSH directly interacts
with viral capsid precursors and mature virions and that
this interaction is required for the formation of an
assembly intermediate (pentameric particles) and conse-
quently infectious progeny. Remarkably, enteroviruses that
were capable of replicating in the absence of GSH
contained a surface-exposed methionine at the protomeric
interface. We propose that GSH is an essential and
stabilizing host factor during morphogenesis and that this
stabilization is a prerequisite for a functional encapsidation
of progeny viral RNA.
Glutathione and Enterovirus Morphogenesis
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Results
TP219 disrupt virus production without affecting viral
RNA replication
We recently described a series of 9-arylpurines that inhibit in vitro
enterovirus replication [29]. From this series, we selected TP219
(designated compound 26 in reference [29]) for further mechanistic
studies (Fig. 1A). TP219 inhibits CVB3-induced CPE in BGM cells
showing a 50% effective concentration of 1760.65 mM with only
little adverse effects on the host cell at high concentrations (Fig. 1B).
TP219 was shown to exert antiviral activity against some
enteroviruses (e.g. coxsackieviruses A16, A21 and A24, CVB3,
echovirus 1 and 9 and poliovirus Sabin 3) but proved inactive
against others (e.g. echovirus 11, poliovirus Sabin 1 and enterovirus
71) (Table 1). Interestingly, a cell type-dependent antiviral effect was
observed. TP219 proved to be active against CVB3, echovirus 9 and
CVA21 in Vero, BGM or MRC-5 cells, but not in HeLa or RD
cells. EV71 and PV Sabin 1 remained insensitive when tested on
Vero or BGM. Thus, TP219 inhibits the replication of a selection of
enteroviruses in selected cell lines.
To explore the mechanism by which TP219 inhibits CVB3
replication, we systematically examined its effect on the different
steps in the virus replication cycle. Towards that end, we used a
reporter CVB3, expressing a Renilla Luciferase gene (RLuc-CVB3)
placed between the 59 UTR and the P1-coding region followed by
a 3CDpro cleavage site allowing for proteolytic processing of the
polyprotein (Fig. 1C). BGM cells were infected with RLuc-CVB3
in the presence or absence of TP219. Geldanamycin and
guanidine HCl (GuaHCl) were used as positive controls. GuaHCl
is a known inhibitor of viral RNA replication; geldanamycin is a
known inhibitor of Hsp90 and was previously reported to inhibit
P1 maturation without affecting viral RNA replication [9]. CVB3
RNA replication was completely blocked in the presence of
GuaHCl, but not in the presence of TP219 and geldanamycin
(Fig. 1C left panel). Lysates of the infected cell cultures were
subjected to end point titration to determine virus yields (Fig. 1C
right panel). In the absence of compound, high virus titers were
measured, indicating that the virus encapsidated the viral genome
efficiently and was capable of infecting new cultures. In contrast,
treatment with TP219 or geldanamycin resulted in a pronounced
Figure 1. TP219 inhibits virus morphogenesis. (A) Structural formula of TP219. (B) Effect of TP219 on cell viability and CVB3-induced cytopathic
effect in BGM cells. Toxicity (black circles) and CPE (white squares) was quantified by MTS assay at 3 d p.i. and expressed as percentage of untreated
controls. Data are average values6 SD. (C) Analysis of the effect of TP219 on RNA replication and infectious virus titers. BGM cells were infected with
RLuc-CVB3. The indicated compounds were added immediately after infection at the indicated concentrations. The enterovirus inhibitors GuaHCl and
geldanamycin were included as controls. At 8 h p.i. intracellular viral RNA replication in the absence or presence of the indicated molecules was
quantified by measuring luciferase activity (C, left panel). Lysates were used to determine infectious virus yields calculated by endpoint titration and
expressed as the tissue culture 50% infectious dose per ml (TCID50) (C, right panel). Experiments were performed in triplicate and mean values6 SD
are depicted. (D) Effect of TP219 on polyprotein processing. Cells were infected with CVB3 at MOI 50 and pulse-labeled with Methionine 3S[S] in the
absence or presence of TP219. Subsequently, proteins were analyzed by SDS-PAGE.
doi:10.1371/journal.ppat.1004039.g001
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reduction of virus titers, indicating that, despite normal RNA
replication levels, no infectious virus particles were formed. Thus,
TP219 treatment did not affect early stages (such as attachment,
entry or uncoating) or RNA replication. The fact that TP219 did
not affect viral RNA replication indicates formation of intact and
functional non-structural replication proteins. The defect in virus
production might however be due to an adverse effect on
3C(D)pro-mediated proteolytic processing of structural capsid
proteins. To test this possibility, CVB3-infected BGM cells were
labeled with [35S]Met both in the absence or presence of TP219
between 5.5 and 6h p.i. (Fig. 1D) [9]. During this period CVB3
efficiently shuts off translation of cellular mRNA hence only viral
proteins are radiolabeled. TP219 was shown not to directly affect
3C(D)pro-mediated proteolytic processing of the capsid-coding
region as normal levels of VP0 and VP1 were observed (Fig. 1D).
However, it cannot be ruled out that TP219 might have an
indirect effect on proteolytic processing by affecting host cell
metabolism which might require longer incubation periods.
Thus, these data demonstrate that TP219 does not inhibit entry,
translation or RNA replication of CVB3, but interferes with virus
morphogenesis.
TP219 interferes with the transition of protomers into
pentamers
The effect of TP219 on the formation of different assembly
intermediates (protomers [5S], pentamers [14S], empty capsids
[75S] and mature virions [150S]) was next studied by sedimen-
tation through a sucrose density gradient and analysis of gradient
fractions by trichloroacetic acid (TCA) precipitation and liquid
scintillation counting. In parallel, buthionine sulfoximine (BSO), a
previously described enzymatic inhibitor of GSH synthesis and
enterovirus morphogenesis, was included as a reference [25].
Mock (Fig. 2A–D), TP219- (Fig. 2A and 2B) or BSO- (Fig. 2C and
2D) treated BGM cells were infected with CVB3. 14S pentamers,
75S empty capsids and the 150S virions were readily detected in
lysates of the CVB3-infected control cultures. Because of the high
background near the top of the 6–25% sucrose gradient (Fig. 2A
and 2C), 5S protomeric particles could not be distinguished. In the
presence of TP219 or BSO, 14S, 75S or 150S assembly
intermediates were not observed in the lysates of the infected
cultures. Thus, TP219, akin to BSO, prevents the formation of
14S assembly intermediates and as a consequence the formation of
consecutive higher-order particles.
To allow a better dissection of the 5S and 14S viral particles
and to reduce interference of labeled cellular and viral material,
every two fractions of the 6–25% gradient were pooled and
subjected to immunoprecipitation using polyclonal anti-CVB
antibodies (Fig. 3A and 3B). Both 5S protomeric particles and
14S pentameric particles were detected in CVB3-infected
control cultures. In analogy to the TCA-precipitated fractions,
14S peaks were largely reduced in the presence of either TP219
(Fig. 3A) or BSO (Fig. 3B). Also the levels of 5S protomeric
particles were somewhat reduced in the presence of both
compounds. Intriguingly, several peaks of unknown nature with
a sedimentation coefficient varying from 5S to 14S appeared.
To further corroborate the above, we next analyzed the effect of
TP219 and BSO on the distribution of VP1 in 6–25% sucrose
density gradient fractions (Fig. 3C–E). We therefore performed
an immunoblotting analysis, using a monoclonal anti-VP1
antibody, on every two consecutive TCA-precipitated fractions
and quantified the immunblot by densitometric analysis.
Considering that protein composition (VP0, VP1 and VP3)
remains intact during the transition of 5S into 14S particles, the
data presented in Figure 3C–E clearly show that, akin to the
immunoprecipitation experiments, TP219- (Fig. 3D) and BSO-
(Fig. 3E) treatment affects the assembly pattern - as represented
by VP1 - and results in a reduction of the levels of 14S
pentameric particles as compared to the DMSO control
(Fig. 3C).
Taken together, these data suggest that both TP219 and BSO
affect the transition of protomeric subunits into pentameric
subunits, or alternatively that they may affect the stabilization of
pentameric particles, thereby resulting in the formation of several
new assembly intermediates.
Table 1. Antiviral activity of TP219 against a selected panel of enteroviruses.
Species Serotype (Strain) Cell line EC50 (mM)
a
Enterovirus A Coxsackievirus A16 (G-10) MRC-5 2.760.76
Enterovirus 71 (BrCr) RD, HeLa, Vero .100
Enterovirus B Coxsackievirus A9 (Bozek) HeLa .100
Coxsackievirus B3 (Nancy) Vero 7.362.3
Coxsackievirus B3 (Nancy) BGM 1760.65
Coxsackievirus B3 (Nancy) HeLa .100
Echovirus 1 (Farouk) BGM 2465.8
Echovirus 9 (Hill) MRC-5 3.361.2
Echovirus 9 (Hill) RD .100
Echovirus 11 (Gregory) MRC-5 .100
Enterovirus C Poliovirus 1 (Sabin) HeLa, Vero, BGM .100
Poliovirus 3 (Sabin) BGM 4067.1
Coxsackievirus A21 (Coe) MRC-5 4.561.6
Coxsackievirus A21 (Coe) RD .100
Coxsackievirus A24 (Clinical) MRC-5 2.760.87
Data are mean values 6 SD from at least three independent experiments. The cytotoxicity values (CC50) were for all cell lines .100 mM.
a50% effective concentration.
doi:10.1371/journal.ppat.1004039.t001
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TP219 rapidly depletes host cell glutathione levels via
formation of an adduct
We next explored whether, TP219 affects like BSO intracellular
GSH levels. Intracellular levels of GSH in TP219- or BSO-treated
BGM cells were monitored over a period of 24 hours. BSO
treatment resulted in a progressive depletion of endogenous
intracellular GSH levels and almost complete depletion
(8960.47%) was observed 24 hours post incubation (Fig. 4A). In
contrast, already following one hour of incubation in the presence
of TP219, the intracellular GSH content was reduced by more
than 90%. GSH levels were completely depleted (9960.048%)
following 3 hours of incubation (Fig. 4A). Conversely, treatment of
HeLa cell cultures with TP219 hardly resulted in any reduction in
GSH levels (Fig. S1). In parallel, we also determined the total
intracellular GSH concentration in BGM and HeLa cells, being
6.360.40 nmol/mg protein and 7.560.18 nmol/mg protein
respectively. It is unlikely that this small difference accounts for
the TP219 insensitivity of HeLa cells. However, it has been shown
previously that tumor cell lines (such as HeLa cells) may have an
increased GSH biosynthesis [30]. This could then result in a rapid
replenishment of the depleted GSH pools following TP219-
treatment. Within this context, it is likely that the differences in
antiviral activity between HeLa (and most likely also RD) and
BGM (and most likely also Vero and MRC-5) (see Table 1) cells
are linked to GSH depletion or the lack thereof.
Figure 2. TP219- and BSO-treatment prevents the formation of 14S particles. Effect of TP219- (400 mM) (A and B, black squares), BSO-
(2 mM) (C and D, black squares) and mock-treatment (A–D, white circles) on 5S, 14S, 75S and 150S assembly intermediates. Treated BGM cells
were infected with CVB3 at a MOI of 10 and lysates were loaded onto 6 to 25% sucrose gradients for a separation of the 5S and 14S subunits (A and
C) or onto 15 to 30% gradients for a separation of 75S and 150S subunits (B and D). Gradients were fractionated from the top, TCA-precipitated and
counted by scintillation. Cartoon representations of the different assembly intermediates are indicated as well.
doi:10.1371/journal.ppat.1004039.g002
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Depletion of GSH can be the consequence of an (i) increased
GSH efflux (ii) increased cellular GSH oxidation or (iii) inhibition
of GSH synthesis. TP219 did not markedly increase levels of
extracellular GSH or intracellular GSSG (oxidized GSH) (data not
shown). Moreover, the kinetic profile of GSH depletion in BSO
treated cells differed from that in TP219-treated cells suggesting a
mechanism of GSH depletion independent from inhibition of
GSH synthesis. GSH is known to react as a nucleophile to form S-
substituted conjugates even in the absence of catalyzing enzymes.
The chlorine at position 6 of the chloropurine TP219 might be
susceptible to a nucleophilic attack by the -SH group of GSH. The
formation of such a conjugate can be determined by high
performance liquid chromatography (HPLC) and mass spectrom-
etry (MS) analysis. To explore this possibility, glutathione ethyl
ester (GEE) (which was used as a surrogate because of its higher
hydrophobicity and MS signal intensity compared to GSH) [31]
was co-incubated with TP219. At different time points after
incubation the samples were analyzed by HPLC. The peak
corresponding to TP219 (retention time (rt) = 12.6 min) was
significantly reduced in function of time with the concomitant
Figure 3. TP219- and BSO-treatment induces the formation of new assembly intermediates. Effect of TP219-, BSO- and mock treatment
on the levels of 5S protomers and 14S pentamers as determined by immunoprecipitation (A–B) and immunoblotting analysis (C–E). (A–B) Two
consecutive fractions of a 6 to 25% gradient were pooled, immunoprecipitated using polyclonal anti-enterovirus antibodies and assayed for
radioactivity. Different immunoprecipitated fractions (bars) are overlaid on TCA-precipitated fractions (lines) (derived from Figure 2) and the amount
of radioactivity is expressed as % of total signal to normalize for the incorporation efficiency. Immunoprecipitated fractions of untreated cultures (A
and B) are indicated in white; TP219- (A) or BSO- (B) treated cultures in black. Cartoon representations of the 5S and 14S assembly intermediates are
indicated as well. (C–E) Two consecutive fractions of a 6 to 25% gradient were pooled, TCA-precipitated and subjected to Western blotting analysis
using a monoclonal anti-VP1 antibody. Both the immunoblot (below) and quantification of the immunoblot (top) of mock (C), TP219- (D) and BSO-
(E) treated cultures are depicted. Sucrose density is indicated as well and expressed as g/cm3.
doi:10.1371/journal.ppat.1004039.g003
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formation of a new peak (rt = 10.7 min) (Fig. S2), which was
analyzed by LC/MS/MS. Accurate mass determination (electro-
spray negative ion mode) indicated a peak with m/z 570.71
(corresponding to C25H28N7O7S) that was assigned as the
conjugate [M-H]2 (Fig. 4B). Collision induced dissociation
(CID) of this anion by MS/MS afforded fragment ions at m/z
300.11, 210.08 and 128.03 (Figure 4B), which have been proposed
as an unambiguous identification of GEE trapped metabolites
[32]. Taken together, these data suggest that TP219 forms an
adduct with GSH, even in the absence of enzymes [31,33].
To confirm the role of GSH in CVB3 morphogenesis, TP219-
treated infected cells were supplied with exogenous GEE (which
has better cell permeability than GSH). This resulted in a
dose-dependent rescue of virus production (Fig. 4C). Since GSH is
essential for maintaining a reduced cellular environment, GSH
depletion might indirectly result in an antiviral status. Therefore,
we studied the effect on virus infectivity of the reducing agents N-
acetyl cysteine (NAC) and dithiothreitol (DTT) compensating for
GSH depletion. In agreement with earlier observations made for
BSO neither of them could serve as a surrogate for GSH (data not
shown) [25].
GSH-independent replication of CVB3 maps to a region
in the capsid at the interface between two protomers
To identify whether we could drive CVB3 to replicate in the
absence of GSH, three independent pools of CVB3 were
Figure 4. TP219 depletes intracellular GSH levels via a covalent bond. (A) Effect of TP219 (black squares) and BSO (white circles) versus
control (black squares) on intracellular reduced (GSH) levels in BGM cells, quantified at various time points post incubation. (B) LC/MS/MS followed by
collision induced dissociation analysis identified the ion [M-H]2 at m/z 570.71 and several fragment ions. Proposed structure of TP219-GEE adduct
corresponding to [M-H]2 is provided as well. (C) The inhibition of infectious particle formation by TP219 can be reversed by a dose dependent
exogenous addition of reduced GSH (GEE) to TP219-treated cell cultures. Control or TP219-treated (50 mM) cell cultures were co-incubated with
varying concentrations of GEE, infected with CVB3 at an MOI of 5 and harvested 7 h pi. Virus titers were calculated by endpoint titration and
expressed as the tissue culture 50% infectious dose per ml (Log10 TCID50). Data are average values 6 SD.
doi:10.1371/journal.ppat.1004039.g004
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repeatedly propagated in the presence of increasing concentrations
of TP219, and thus decreasing concentrations of GSH. Following
17 sequential passages, several GSH-independent variants
emerged that replicated (in contrast to the wildtype (wt) virus)
effectively in the absence of GSH. To delineate the genetic basis
for the observed resistance to GSH depletion, the complete
nucleotide sequence of the three selected variants was determined
and compared with the wt viral genome. In all three mutant pools
a T77M mutation in VP1 in combination with one or two
Figure 5. Growth phenotype of TP219-resistant CVB3 recombinants. The genomic organization of the structural proteins of CVB3
recombinants are illustrated on the left. Mutations in the genomic structure of P1 are shown by black rectangles. Virus infectious virus yields were
calculated by endpoint titration and expressed as the tissue culture 50% infectious dose per ml (Log10 TCID50/ml). The plaque phenotype was
determined using a plaque assay.
doi:10.1371/journal.ppat.1004039.g005
Table 2. Amino acid mutations identified in three CVB3 pools
following selection of GSH-insensitive variants.
Nucleotide
CVB3
protein
Amino Acid
Substitution Substitution Position Pool
VP3 K115R AAGRAGG 1337 2
VP3 A180T GCTRACT 1531 1
VP1 T77M ACGRATG 1937 1,2,3
VP1 V150I GTARATA 2155 3
VP1 N212S AACRAGC 2342 2
2A E54K GAGRAAG 2797 1,2
2A E59V GAARGTA 2813 1,2
3A I22V ATTRGTT 4348 1,2
3A K39R AAARAGA 4400 1,2
doi:10.1371/journal.ppat.1004039.t002
Table 3. Resistance pattern of recombinant CVB3 viruses
carrying mutations in VP1 and VP3, either alone or combined.
Mean EC50 [mM] ± SD of indicated antiviral
molecule
Clone Mutation TP219 Enviroxime TBZE-029 BSO
Wild-Type 7.362.3 0.8460.23 4.460.21 8767.8
1 T77M .100 0.4960.012 4.661.0 .2000
2 V150I 5.562.0 0.8060.044 2.260.22 ND
3 N212S 6.560.17 0.3860.18 3.160.67 ND
4 K115R 1469.3 0.1460.080 2.961.0 ND
5 A180T ND ND ND ND
6 T77M+V150I .100 0.5260.034 4.460.91 .2000
7 T77M+N212S .100 0.2160.051 2.860.74 .2000
8 T77M+A180T .100 0.4660.048 2.261.9 .2000
Recombinant viruses were evaluated for inhibition by TP219, enviroxime, TBZE-029
and BSO.
Data represent EC50 values [mM] 6 SD.
ND, not determined.
doi:10.1371/journal.ppat.1004039.t003
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mutations in VP1 (V150I and N212S) or VP3 (A180T and K135R)
(Table 2) was observed. A number of other mutations (in 2A and
3A) were not further considered, since they did not occur in all 3
variants. To assess the precise contribution of the identified
mutations to the GSH-independent phenotype, recombinant
viruses were engineered. Seven constructs were generated
containing the identified mutations, either alone or combined,
and RNA transcripts were transfected into BGM cultures.
Mutation T77M alone (or combined), proved sufficient to bypass
the need for GSH (Table 3). Constructs containing solely VP1
mutation V150I or N212S or VP3 mutation K115R still demon-
strated a GSH-dependent phenotype. The T77M mutant CVB3
proved also cross-resistant with BSO (Figure S3). Virus titers and
the plaque phenotype of the different resistant viruses were similar
to that of the wt virus, which might be indicative for a comparable
viral fitness, at least in vitro (Fig. 5). Only the T77M/N212S mutant
produced smaller plaques than wt virus, which may suggest a role
for the additional K115R mutation in VP3 that was not
reintroduced into the genome of the T77M/N212S mutant.
Structural analysis of GSH-independent enteroviruses
The capsid of a mature virion consists of 60 protomers, each
protomer consisting of a single copy of structural proteins VP1,
VP2, VP3 and VP4, arranged on a pseudo T=3 icosahedral
surface [34]. Viral capsid proteins VP1, VP2 and VP3 are partially
located at the outer surface of the capsid and adopt a similar eight-
stranded antiparallel b-barrel fold which is conserved among
enteroviruses. The antiparallel b-sheet barrel of VP1 harboring
Thr-77 (the main mutation conferring GSH insensitivity that was
identified in the revertant screen (Table 2), consists of bC, bH, bE
and bF, and bB, bI, bD and bG which are packed face-to-face
[35]. The Thr-77 is predicted to be a solvent exposed residue and
is positioned in the bB, flanking the rim of the canyon closest to the
fivefold axes [34]. Interestingly, the VP1 (Val-150 and Asn-212)
and VP3 residues (Ala-180) are, akin to the Thr-77 residue,
exposed on the surface of the CVB3 [M strain (1COV)] capsid and
line the canyon surrounding the fivefold axis point (Fig. 6A).
Although dispersed throughout the viral genome in the linear
amino acid sequence, the identified amino acids all reside in close
proximity to each other on the surface wall and more specifically
opposing each other at the interface between protomeric subunits.
Next, we wondered whether the lack of activity of TP219
against several enteroviruses, including enterovirus 71 and
echovirus 11 (Table 1), resulted from a natural resistance to
GSH-depletion and whether this could be linked to a structural
functionality. Within this context we analyzed the available
crystallographic structures for the presence of a solvent exposed
methionine, the main mutation conferring GSH-independence in
Figure 6. Resistance to GSH depletion maps to the interface between 2 protomers. (A) Surface rendered view of a single pentameric
subunit (colored) in a whole capsid of CVB3 strain M (PDB 1COV). The remaining surface of the virion is colored grey. Viral proteins within a single
pentameric unit are colored denoting VP1 (yellow), VP2 (green) and VP3 (aquamarine). A pentameric unit showing the location of the different
mutations conferring GSH-insensitivity identified from the revertant screen (red) at the interface of 2 protomers. One protomer within the pentameric
structure is outlined and an enlarged view on the antiparallel b-sheets in VP1 (colored yellow) and the location of the identified amino acids (colored
red) on the interface between two protomers is provided as well. Comparison of pentamers of various GSH-insensitive (B) [echo11 (1h8t) and EV71
(4aed)] and GSH-sensitive (C) [CVB3 (1cov), echo 1 (1ev1), CVA21 (1z7s) and RV14 (1ro8)] enteroviruses. Surface representation of different protomers
within a pentamer. Surface exposed methionines are indicated in red. An enlarged view on the location of the identified surface exposed methionines
(colored red) on the interface between two protomers is also provided. Molecular graphics and analyses were performed with the UCSF Chimera
package. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco
(supported by NIGMS P41-GM103311) [58].
doi:10.1371/journal.ppat.1004039.g006
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CVB3 escape mutants. Rhinovirus 14 was also included in the
analysis since this virus proved to be sensitive to GSH depletion in
BSO-treated HeLa cells (data not shown). The naturally resistant
viruses were found to be already carrying a solvent exposed
methionine at the interface between two protomers (Fig. 6B). This
methionine was not present in the GSH-dependent viruses
(including echo1, CVA21 and RV14) (Fig. 6C). The assumed
GSH-independence of echo11 and EV71 could be mapped to
respectively a methionine at location 76 (positioned on the bB
sheet) and 229 (positioned on the bH sheet) in VP1.
Glutathione interacts directly with the capsid and is
essential for morphogenesis/encapsidation
The assembly defect following GSH depletion likely results from
the requirement for a direct interaction between GSH and the
capsid. It has been described previously that capsid-binding
molecules (e.g. pleconaril [36]) can protect against thermal-
mediated inactivation by direct binding to and stabilizing of the
virus particle [37]. We therefore incubated wt, T77M and T77M/
A180T CVB3 at 46uC, a temperature detrimental for wt CVB3
infectivity, in the absence or presence of increasing concentrations
of GSH. Wildtype CVB3 displays a temperature-sensitive pheno-
type, which is reversed upon addition of GSH (Fig. 7A).
Interestingly, the infectivity of the T77M and T77M/A180T
CVB3 remains almost unaffected at this temperature. These data
strengthens the hypothesis that GSH interacts directly with the
viral capsid thereby rescuing virus infectivity during heat
inactivation. Thus, introducing a methionine at position 77 in
VP1 generates a GSH-independent and temperature-insensitive
phenotype.
To provide biochemical evidence for the interaction between
GSH and the capsid, GSH-pull down assays were carried out
(Fig. 7B). BGM cell cultures were infected with wt CVB3 after
which the lysates were co-incubated with glutathione-sepharose
beads and assayed for GSH affinity. Autoradiographic analysis
clearly reveals that GSH is able to pull down VP0, VP1, VP2 and
VP3 (lane 2 and 29). Under these conditions of the gel, VP4 cannot
be detected. Interestingly, the pull down mix contains both VP0
and VP2 which is indicative for the presence of both mature and
precursor virus interacting with GSH.
To further corroborate this observation and to assess the GSH-
binding properties of a GSH-independent enterovirus, Vero cells
were infected with PV Mahoney, being a GSH-dependent virus
(observed by Ma et al. in the accompanying paper) and PV Sabin
1, being a natural GSH-independent virus (Table 1). In addition,
we assessed the effect of TP219-induced GSH depletion on this
GSH-binding (Fig. 7C). As expected, no maturation cleavage of
VP0 into VP2 and VP4 could be observed in TP219-treated cells
infected with PV Mahoney (compare lanes 1 and 2), indicating
that no infectious particles were formed, whereas this cleavage was
readily observed for the GSH-independent PV Sabin 1 (compare
lanes 3 and 4). Akin to CVB3, capsid proteins could be readily
detected in the pull down of untreated cell lysates infected with
both PV Mahoney (line 5) and PV1 Sabin 1 (line 7). However,
upon TP219-induced GSH depletion capsid proteins of PV
Mahoney, but not those of PV Sabin 1, lost their GSH-binding
properties (compare lanes 6 and 8).
Together, these observations suggest that GSH interacts with
enterovirus capsid proteins and that following GSH depletion,
GSH-dependent viruses, unlike GSH-independent viruses, lose
their GSH-binding properties.
Glutathione is required for capsid proteins to localize in
close vicinity of the replication sites
It has been shown that (i) 5S and 14S particles associate with
vesicular membranes containing the RNA replication complexes
[38] and that (ii) encapsidation of progeny viral RNA is governed
by a direct interaction between VP3 (possibly as part of these 5S or
14S particles) and replication protein 2C [20,21]. More specifically
a role for residue Glu-180 in VP3 (located at the interface of two
protomers) was demonstrated to be an essential contact point with
protein 2C. Intriguingly, the genetic evidence described above also
implicates this region in GSH-independence. Therefore the
impact of GSH depletion on the subcellular (co-)localization of
Figure 7. Direct interaction between VP1 and GSH. (A) Heat inactivation of 36107 TCID50/ml of wt, T77M and T77M/A180T CVB3 in the absence
or presence of various concentrations of GSH. Following 30 minutes incubation at 46uC infectious virus titers were determined and expressed as
Log10 TCID50/ml. (B) GSH pull down assay using glutathione-sepharose beads of CVB3-infected BGM cells. Labeling was done with Methionine
3S[S]
and the lysate was analyzed by SDS-PAGE for the presence of viral proteins (input, lane 1). The lysate was loaded onto glutathione-sepharose beads
and analyzed by SDS-PAGE (GSH pull down, lane 2). Lane 29 shows a shorter exposure time of lane 2. (C) GSH pull down of PV Mahoney or PV Sabin1
infected Vero cells that were treated with TP219 or left untreated. Lysates were analyzed by SDS-PAGE (input, lanes 1–4) and loaded onto GSH
Sepharose beads after which the pulled down material was analyzed by SDS-PAGE (pull down, lanes 5–8).
doi:10.1371/journal.ppat.1004039.g007
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VP1 and protein 2C in cells infected with either wt, T77M and
T77M/A180T CVB3 was studied. Both in the absence and the
presence of GSH, protein 2C of both wt and mutant CVB3
showed a distinct reticulated pattern in the perinuclear region
(Fig. 8), suggesting that GSH depletion had no effect on the
localization of protein 2C as part of the replication complex. This
is also in line with the above observation that depletion of GSH
levels does not inhibit viral RNA replication. In the absence of
TP219 (i.e. in the presence of GSH), VP1 and 2C of both wt and
the T77M CVB3 were observed to colocalize. Similar results were
observed for T77M/A180T (Fig. S4). However, in the presence of
TP219 (i.e. in the absence of GSH), VP1 of wt CVB3 showed a
more dispersed pattern and no longer co-localized with protein
2C. Hence, GSH might be essential for localizing VP1,
presumably as part of a 5S or 14S assembly intermediate, to the
sites of replication allowing the encapsidation of newly synthesized
viral RNA. Importantly, introducing a surface-exposed methio-
nine in the capsid (T77M) resulted in a relocalization of VP1 to the
replication sites even in the absence of GSH.
Discussion
We here describe the discovery of TP219 as a novel inhibitor of
the replication of several enteroviruses. We showed that TP219
forms a covalent adduct with GSH in an enzyme-independent
way, thereby rapidly depleting intracellular GSH levels. As a
consequence, the formation of infectious progeny virus is
prevented without interfering with earlier events in the viral life
cycle, such as entry, translation, proteolytic processing and RNA
replication. By employing TP219, we further studied the details of
virus assembly and present several lines of evidence that GSH is
required during the transition of protomeric particles into
pentameric particles. Inhibition of virus assembly following GSH
depletion was not rescued by treatment with other reducing
agents, indicating that a reducing environment is not a require-
ment for morphogenesis. We provided biochemical and micro-
scopical evidence for a direct interaction between VP1 and GSH
and that this interaction is essential for the translocation of
assembly intermediates to the sites of replication. Furthermore,
genetic and structural analysis of several GSH-independent viruses
point towards the interface between protomers as a region critical
for GSH binding/independence.
Capsid proteins VP1, VP2 and VP3 have the conserved b-
sandwich motif consisting of eight-stranded antiparallel b-sheets
packed face-to-face [35]. It has been previously suggested that
modulation of the interface between protomers might be a
mechanism shared by enteroviruses for the control of structural
transitions during morphogenesis [39]. Within this context, it may
be plausible that intact b-sheets at the protomeric interface are a
prerequisite for morphogenesis and that (a) residue(s) within the b-
barrel region interact with GSH, thereby modulating or stabilizing
energetically favorable interactions that promote virus assembly.
Indeed, fractionation studies revealed that in the absence of GSH
the formation of pentameric particles was prevented without
affecting the levels of protomers. These data suggest that GSH is
needed for the transition into or the stabilization of pentameric
particles required for assembly into higher-order particles.
Upon sequential passaging of (GSH-dependent) CVB3 in the
presence of suboptimal levels of GSH, three GSH-independent
variants were obtained. These virus isolates all contained a
surface-exposed T77M mutation positioned in the bB-sheet of VP1
at the protomeric interface. Introducing this methionine into the
wildtype CVB3 genome fully rescued the production of progeny
virus, indicating that a single residue can mimic the presence of
GSH. In addition, our antiviral data showed that some viruses, e.g.
EV71 and echovirus 11, proved to be naturally insensitive to
GSH-depletion. Genetic analysis of the available crystallographic
structures of these GSH-insensitive viruses revealed the presence of
a similar solvent-exposed methionine at the interface between two
protomers. This further supports the hypothesis that GSH (or a
surface-exposed methionine) may promote stabilization of b-sheets
at the interface between protomers allowing further assembly into
pentamers. Taking into account that GSH is an essential
component of the cellular metabolism and is present at very high
concentrations in mammalian cells, the natural presence of a
surface exposed methionine in the capsid of several enteroviruses
suggests that these viruses may already have evolved to assemble in
the absence of glutathione despite the lack of a selective pressure
(thus the absence of GSH). Whether the presence of a surface
methionine represents a beneficial mutation conferring fitness
advantage as also the question why most viruses do not already
carry this residue remains to be answered.
Since addition of other sulfhydryl reducing agents such as DTT
and NAC could not substitute for GSH, it seems unlikely that the
apparent requirement for GSH during virus assembly results from
an imbalance of the intracellular redox status or from an indirect
effect on local pH which in turn has been reported to be important
during assembly of bovine enterovirus in vitro [40]. This could
indicate that GSH is directly rather than indirectly involved in the
formation of pentameric particles. This was confirmed by
employing a biochemical assay in which we demonstrated that
GSH directly interacted with capsid proteins VP1, VP2, VP3 and
Figure 8. GSH depletion interferes with the interaction of VP1 and 2C. BGM cells were infected with wt or T77M CVB3 at a MOI of 10, in the
absence or the presence of 50 mM TP219. Cells were fixed with saponin 0.5% at 5 h p.i. and costained with antibodies targeting 2C (and Alexa Fluor
568-conjugated secondary antibody (red color)) and VP1 (and Alexa Fluor 488-conjugated secondary antibody (green color)). Regions of
colocalization are indicated by arrows.
doi:10.1371/journal.ppat.1004039.g008
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VP0 of CVB3, PV (M) and PV Sabin 1. Further evidence for this
direct interaction between the capsid and GSH was provided by
heat inactivation experiments. The temperature sensitive (ts)
phenotype of wt CVB3 is suppressed upon addition of GSH or
changed to a temperature insensitive (non-ts) phenotype upon
introducing a methionine at Thr-77. The fact that GSH (and
methionine) is (are) capable of stabilizing virus infectivity
following heat inactivation is in line with previous obser-
vations for capsid binding agents that, by direct binding to the
virion, are also capable of rescuing infectivity following thermally
induced conformational rearrangements [37,41]. We therefore
propose a critical role for GSH as a direct binding and stabilizing
cofactor in the interaction between protomeric units assembling
into pentameric particles. This hypothesis was further corrobo-
rated by biochemical assays showing a loss of GSH-binding
properties of PV Mahoney capsid proteins following TP219
treatment and suggests that GSH depletion results in malformed
protomeric particles that are unable to interact with GSH and also
unable to fully assemble into pentameric particles. Remarkably,
GSH-independent enteroviruses retain their GSH-affinity albeit
this affinity is no longer required for assembly. Likewise, it has
been shown that the temperature sensitivity of PV3/Sabin could
be attributed to a S91F substitution in VP3 at the interface
between protomers which resulted in the impaired formation of
14S pentameric particles at supraoptimal temperatures [39,42].
Since non-ts revertants contained a number of second-site
mutations, GSH or a surface-exposed methionine could in a
similar way suppress conformational changes induced by heat
inactivation.
It was recently shown that encapsidation of progeny viral RNA
is directly linked to an interaction between VP3, (possibly as part
of a pentameric particle), and non-structural protein 2C [20].
More specifically, Glu-180 in VP3 at the interface of 2 protomers
was suggested to be an essential determinant for interaction with
protein 2C. Further evidence for a direct interaction of 2C with
capsid proteins was provided by a study in which several mutations
in VP1 and VP3 were identified to compensate for a defect in
encapsidation [22]. Despite the fact that 2C and capsid precursors
(protomeric and pentameric particles) have been shown to co-
localize at the surface of replication vesicles and can be cross-
linked to viral RNA, it is still unknown whether 2C interacts
directly with VP1 or VP3 or with a higher-order assembly
intermediate [38,43]. Our fractionation studies revealed almost
exclusively protomers in TP219-treated cells. Strikingly, we
observed an altered subcellular co-localization pattern of 2C and
capsid protein VP1 (presumably as part of a protomeric particle) in
TP219-treated cells by confocal analysis. On the contrary, the
presence of a surface-exposed methionine resulted in a relocaliza-
tion of VP1 to the sites of replication independent from GSH.
Thus, GSH (or its ‘‘surrogate’’ T77M) proves essential for
localizing assembly intermediates to the sites of replication. It is
tempting to speculate that GSH is required for transition of
protomers into pentamers and that pentamers are a prerequisite
for a functional interaction with protein 2C. However, it cannot be
formally ruled out that GSH depletion might also result in
misfolded protomeric particles, resulting in a loss in the capacity to
interact with 2C.
Intriguingly, GSH depletion following BSO-treatment in
CVB3-infected HeLa cells was earlier shown not to affect the
levels of protomeric and pentameric particles, but increased the
levels of empty capsid particles [25]. In addition, Ma et al. observed
an accumulation of pentameric particles and slightly faster
sedimenting 150S particles in BSO-treated PV (M)-infected HeLa
cell cultures [accompanying paper]. By contrast, our fractionation
studies revealed the absence of pentameric and empty capsid
particles in both BSO-treated and TP219-treated cells. It remains
to be studied whether the use of strain CVB3/0 or PV1 (M) and
HeLa cells instead of a Nancy CVB3 and BGM cells (our study)
explains this difference.
Our data suggest that formation of infectious progeny involves
the recruitment of assembly intermediates to a membranous
surface containing the RNA replication complex. It has been
demonstrated that the N-terminal glycine of VP4 is cotranslation-
ally modified with a myristic acid linking each protomer within the
pentameric structure to the two adjacent protomers at the 5-fold
axes thereby stabilizing the structural elements within a penta-
meric unit [15]. Despite the fact that non-myristoylated proto-
meric particles can be found at the site of replication [13] and that
purified non-myristoylated capsid proteins can assemble in
solution into virus like particles [44], it has also been demonstrated
that myristoylation might be a determinant for a correct
membrane targeting of cytoplasmatically processed protomers
[45]. However, since a N-myristoyl group confers only low
hydrophobicity, additional (hydrophobic) factors may be required
to improve membrane affinity [46,47]. Within this perspective, we
hypothesize that the tethering of myristoylated-protomers to
membranous replication vesicles is enhanced by GSH or the
presence of a methionine. Indeed, it has been recently suggested
that glutathionylation of activated S100A9, a calcium-binding
protein involved in fatty acid (FA) transport in neutrophils, might
facilitate the interaction of S100A9 with the lipid environment
during the translocation from the cytosol to the membrane,
probably by increasing protein hydrophobicity [48]. Similarly, the
presence of a surface exposed methionine, one of the most
hydrophobic amino acids, has been described to be a key regulator
for tight phospholipid membrane binding [49–51]. Albeit based on
much speculation, methionine or GSH could then generate a
hydrophobic surface region that increases membrane affinity
following N-myristoyl-guided membrane targeting. Translocation
of protomers to membranes may increase the change to encounter
other protomers to form pentamers and, hence, the efficiency of
assembling into higher order particles.
It remains unclear how GSH interacts with capsid proteins. Our
data suggest that GSH is capable of interacting with capsid
proteins both during and after maturation into infectious virus
particles. This idea is supported by fractionation studies on sucrose
gradients (showing that GSH is involved in the transition of 5S
into 14S) and by heat inactivation (showing that GSH interacts
with the infectious virion) and pull down experiments (demon-
strating the presence of both VP0 and VP2 following GSH-pull
down). In addition, in the accompanying paper Ma et al.
demonstrate that capsid proteins can be readily detected following
GSH-pull down of purified assembly intermediates. Despite the
fact that these data suggest that GSH can interact with the
maturing particle, GSH has not been observed in crystallographic
structures for which several reasons could be hypothesized: the
purification process might have resulted in the loss of GSH or
GSH might be displaced by an unknown mechanism during/after
morphogenesis. It might also be worth to explore in more detail
whether unexplained electron densities exist in particles that may
explain the presence of GSH. This might also be interpreted to
mean that GSH interacts with capsid proteins probably in a non-
covalent way which is corroborated by the fact that capsid proteins
can be detected following pull down experiments using GSH-
sepharose beads. In this system, the GSH ligand is attached to
sepharose by a coupling via its sulfhydryl-group to the linker,
implying that viral capsids show affinity for GSH without the
apparent involvement of a SH-group. This also implies that (i)
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GSH does not form disulfide bonds with free cysteines in the viral
capsid and (ii) opens the possibility that this free SH-group might
be the determinant for a correct assembly process. Indeed, genetic
analysis of GSH-independent viruses resulted in the identification
of methionine – another sulfur containing amino acid - as the main
determinant for GSH-independence. Further research is warrant-
ed to provide more details on this interaction and to clarify why
GSH has not been observed thus far in the atomic structures of
purified virus particles.
Reducing agents, including GSH and NAC have been
frequently described to act as an non-conventional antivirals
inhibiting the replication of several viruses, including HSV-1,
HIV-1, influenza, and Sendai virus via various mechanisms [28].
This is the first paper, to our knowledge, that describes in detail
the dependency of virus replication on GSH.
Glutathione is the most potent intracellular reductant in the cell
and is implicated in various cellular processes, including signal
transduction pathways, gene expression, cell proliferation or cell
death [27]. Consequently, an imbalance in GSH has been
associated with various pathologies, including neurodegenerative
disorders and cystic fibrosis. In recent years a dysregulated GSH
system has also been associated with the development of tumor
chemoresistance, mostly by GST-mediated GSH conjugation to
chemotherapeutic agents, resulting in less toxic GSH-drug
complexes that are readily exported from the cell. It is expected
that understanding these mechanisms will not only increase
therapeutic response but will also decrease drug resistance [52,53].
Within this context, TP219 could be a useful tool to study the
direct impact of GSH depletion (by omitting long incubation
periods as for BSO) on chemosensitivity in resistant tumors as well
as the role for GSH in other processes such as virus replication.
Materials and Methods
Cells and reagents
BGM, HeLa, Vero, RD and MRC-5 cells were maintained in
MEM (Gibco), supplemented with 10% fetal bovine serum (FBS)
(Integro), 1% bicarbonate (Gibco) and 1% L-glutamine (Gibco).
The synthesis of TP219 is described elsewhere [29]. Enviroxime
was synthesized by Dr. G. Pu¨rstinger (Institut fu¨r Pharmazie,
Universita¨t Innsbruck, Austria). Geldanamycin was from Biovision
(Milpitas). L-Buthionine sulfoximine (BSO), guanidine hydrochlo-
ride (GuaHCl), N-acetyl cysteine (NAC), glutathione (GSH),
glutathione ethyl ester (GEE) and dithiothreitol (DTT) were
purchased from Sigma Aldrich.
Viruses and antibodies
Coxsackievirus B3 (CVB3) was obtained by transfecting in vitro-
transcribed RNA derived from plasmid p53CB3/T7 as previously
described [54]. This plasmid contains a full length cDNA of CBV3
strain Nancy behind a T7 RNA polymerase promotor [55]. CVB3
expressing Renilla luciferase (RLuc-CVB3) was obtained by
introducing the Renilla luciferase coding sequence between the
59 untranslated region and the P1 coding region. The luciferase
protein is followed by a 3CD cleavage site allowing posttransla-
tional cleavage from the polyprotein by 3CDpro. Poliovirus Sabin 1
and 3 strains were from Prof. B. Rombaut (Vrije Universiteit
Brussels, Belgium). Enterovirus 71 (BrCr), CVA16 (G-10) and
CVA21 (Coe) were obtained from the National Institute for Public
Health and Environment (RIVM, the Netherlands). CVA9
(Bozek), echovirus 9 (Hill) and echovirus 11 (Gregory) kindly
provided by Dr. K. Andries at Janssen Pharmaceutica (Beerse,
Belgium). For immunoprecipitation of sucrose gradients we used
pooled rabbit polyclonal anti-enterovirus antibodies (including
CVB1, 2 and 3) (Accurate Chemical and Scientific Corporation).
For immunofluorescence or immunoblotting, we used as primary
antibodies a mouse monoclonal anti-CVB3 VP1 (Dako) and a
rabbit polyclonal anti-CVB3 2C (kindly provided by Prof. L.
Whitton, Scripps Research Institute, USA). The secondary
antibodies included Alexa Fluor 488-conjugated goat anti-mouse
or 568-conjugated donkey anti-rabbit for immunofluorescence and
goat-anti-mouse-IRDye680 for immunoblotting.
Virus infections
For single cycle virus infections, virus was added to subconfluent
cell layers and allowed to adsorb for 1 hour, after which virus was
removed and fresh (drug-containing) medium was added to the
cells. At 8 h p.i., cells were subjected to three cycles of freeze-
thawing after which virus titers were determined by endpoint
titration. Alternatively, cells were lysed to determine the intracel-
lular Renilla luciferase activity with the Renilla Luciferase Assay
System (Promega). For multicycle virus infections, cells grown to
confluency in 96-well plates were subjected to serial dilutions of the
compound and inoculated with the appropriate virus. After 3 days
of incubation, cell viability was measured: after removal of the
medium, 10% MTS/PMS (Promega) was added to each well and
quantified spectrophotometrically at 498 nm in a microplate
reader. The 50% effective concentration (EC50) was defined as
the concentration of compound that inhibited virus-induced
cytopathic effect formation by 50% and was calculated using
logarithmic interpolation.
Analysis of viral polyprotein processing in vivo
In vivo pulse-chase metabolic labeling studies were performed as
described previously [56]. Briefly, BGM cells, grown to confluency
in a 24-well plate were infected with CVB3 at a multiplicity of
infection (MOI) of 50. At 5 h p.i., the cells were starved for
methionine by replacing the medium with methionine-free
medium for 30 min. Subsequently, the cultures were pulse-labeled
in methionine-free medium containing 35S-labeled methionine for
30 min in the absence or presence of TP219 (50 mM final
concentration). At 6 hours p.i., the cells were washed with PBS,
lysed, and translation products were analyzed on a 12,5%
polyacrylamide gel containing SDS, fixed, and then exposed to
Kodak XAR film.
Analysis of assembly intermediates by sucrose gradient
ultracentrifugation
BGM cells grown to confluency in 75 cm2 flasks were infected
with CVB3 at an MOI of 10. Following a one hour adsorption
period, TP219 (400 mM) was added in complete medium. BSO-
treated (2 mM) cells were pre-incubated for 48 hours. At 3.5 h
post-infection, cells were starved for methionine by replacing the
medium with methionine-free medium. Following a 30 minute
incubation period, the cultures were pulse-labeled in methionine-
free medium containing 35S-labeled methionine (20 mCi/ml). At
6 h. p.i., the cells were washed three times with 1% of ice-cold
unlabeled methionine. Following three cycles of freeze-thawing,
equal volumes of supernatants were loaded onto 6 to 25% sucrose
gradients (wt/vol) for a separation of the 5S and 14S subunits or
onto 15 to 30% (wt/vol) for a separation of 75S and 150S subunits.
Gradients were centrifuged at 39,000 rpm in a Beckman SW40
rotor for 16 h (6 to 25% gradients) or 2 h 15 min (15 to 30%
gradients). Gradients were fractionated in 400 ml aliquots from the
top and precipitated using trichloroacetic acid (TCA). The
radioactivity present in each fraction was quantified by liquid
scintillation counting.
Glutathione and Enterovirus Morphogenesis
PLOS Pathogens | www.plospathogens.org 13 April 2014 | Volume 10 | Issue 4 | e1004039
Immunoprecipitation of viral particles
Immunoprecipitation studies were performed as previously
described [57]. Briefly, every two consecutive samples of a sucrose
gradient were pooled and immunoprecipitated using rabbit
polyclonal anti-CVB3 antibodies. Following a 1 hour incubation
period at 4uC, a 10% suspension of fixed Staphylococcus aureus
strain Cowan I was added. Following 30 min incubation at 4uC,
the samples were centrifuged for 5 min at 4uC. The immunopre-
cipitates were resuspended in NET buffer (150 mM NaCl, 5 mM
EDTA, 50 mM Tris, 0.05% Triton X-100, 0.1% bovine serum
albumin, 0.2% methionin and 0.1% cysteine) and centrifuged for
5 min at 4uC. The immunoprecipitates were resuspended in 2%
SDS and boiled for 5 min. Finally, following centrifugation, the
resulting supernatants were assayed for radioactivity by liquid
scintillation counting.
Immunoblotting analysis of assembly intermediates
TCA-precipitated fractions of a sucrose gradient were subjected
to SDS-PAGE, transferred to a PVDF membrane, incubated with
primary antibody and secondary antibodies and scanned using an
Odyssey Imager (Li-COR). Densitometry was performed on
immunoblot images using the ImageJ gel analysis tool.
Detection of intracellular reduced and oxidized
glutathione
Cells grown to confluency in 96-well plates were incubated in
the presence or the absence of 50 mM TP219. At the indicated
times post treatment with reduced glutathione (GSH) and oxidized
glutathione (GSSG) levels were measured using the GSH/GSSG-
Glo Assay (Promega) according to the recommendations of the
manufacturer.
High-performance liquid chromatography (HPLC) and
mass spectrometry (MS) analysis
TP219 (10 mM) and glutathione ethyl ester (2 mM; pH 7.4)
were co-incubated at 37uC. Samples were taken at four different
time points (0, 3, 6 and 24 h) and analyzed by HPLC. HPLC
spectra were recorded on a Agilent 1120 compact LC instrument
using a diode array detector (230 to 400 nm) and an analytical
ACE 5 C18-300 column (4.6 mm615 cm) at a flow rate of 1 mL/
min. Solvents used were acetonitrile (solvent A), and H2O (0.05%
TFA) (solvent B). The gradient was used as follows: a 2 to 10% in
7 min (solvent A) followed by a 10 to 100% in 8 min (solvent A).
Mass spectrometry analysis was performed using a HPLC-Waters
12695 connected to a Waters Micromass ZQ spectrometer
(column: Sunfire C18, 4.6650 mm, 3.5 mm particle size). Solvents
used were acetonitrile (solvent A) and H2O (0.1% formic acid)
(solvent B). A 15 to 95% gradient (solvent A) was carried out in
5 min (1 mL/min). Electrospray ionization, positive ion mode;
capillary voltage 3.5 kV, cone voltage 30 V.
Isolation of resistant CVB3
TP219 resistant (GSH-independent) CVB3 was generated by
culturing CVB3 in the presence of increasing concentrations of
TP219. After 3 days of incubation, lysates from those cultures that
exhibited CPE in the presence of the highest concentration of
compound were collected and were used to infect new cell
monolayers for successive rounds until viral replication was observed
at concentrations that do not allow replication of wt virus.
Subsequently, viral RNA was isolated (Macherey-Nagel) and both
DNA strands were sequenced [cycle-sequencing method (ABI Prism
Big Dye Terminator Cycle Sequencing Ready Reaction Kit)] using
an ABI 373 Automated Sequence Analyzer (Applied Biosystems)
Site-directed mutagenesis
Mutant CVB3 clones were constructed, containing either
single or multiple amino acid replacements at diverse positions in
the capsid region. The eight clones were designated
CVB3[T77M], CVB3[V150I], CVB3[N212S], CVB3[K115R],
CVB3[A180T], CVB3[T77M/V150I], CVB3[T77M/N212S],
CVB3[T77M/A180T]. The following synthetic oligonucleotides
(and their complementary reverse oligonucleotides) were used for
site-directed mutagenesis of the single mutants: (CVB3[T77M])
59- A TGT AGG TCA GCA TGC GTG TAC TTT ATG GAG
TAT AAA AAC TC -39, (CVB3[V150I]) 59- GTA CCA CCA
GGT GGA CCT ATA CCA GAT AAA GTT GAT T -39,
(CVB3[N212S]) 59- GC ATC AAC ACG CTA AAC AGC ATG
GGC ACG CTA TAT G -39, (CVB3[K115R]) 59- CA CAT
TGG TCA GGC AGC ATA AGG CTT ACG TTT ATG TTC
T -39; (CVB3[A180T]) 59- ACA CAC TAC CGG TTT GTT
ACT TCA GAT GAG TAT ACC G -39; The mutated sequences
are underlined. Site-directed mutagenesis was performed with
plasmid p53CB3/T7 using the XL Blue Large Site-directed
mutagenesis kit (Stratagene), according to the manufacturer’s
instructions. After mutagenesis, the individual clones were
verified by sequencing. The double mutants CVB3[T77M/
V150I] and CVB3[T77M/A180T] were generated by cloning the
single mutant CVB3[V150I] and CVB3[A180T] into
CVB3[T77M] using respectively enzymes EcoRI/SpeI and
BglII/SpeI. The double mutant CVB3[T77M/N212S] was
generated by introducing the mutation at position N212S into
CVB3[T77M] using mutagenesis. Next, enzymes BglII/SpeI were
used to isolate the fragment containing the desired mutations,
and reintroduce in an original, non-mutagenized clone of the
same plasmid p53CB3/T7. From these mutants, RNA transcripts
and infectious viruses were generated as described previously
[54].
Viral plaque assays
For determination of viral plaques, BGM cells, grown to
confluency in six-well plates, were infected with the appropriate
virus at 37uC. After 1 h, the virus was removed and the growth
medium was replaced with agarose. Giemsa solution was used to
stain the cells.
Heat inactivation experiments
Wildtype, T77M and T77M/A180T CVB3 were incubated with
GSH for 15 min at room temperature and subjected to heat
treatment by incubation for 30 min at 46uC either in the absence
or presence of various concentrations of GSH after which virus
titers were determined by endpoint titration.
GSH-pull down experiments
TP219-treated BGM or Vero cells were infected with CVB3,
PV Mahoney or PV Sabin 1 (MOI 10), labeled with 35S-
Translabel 4–6 hr post-infection and harvested in TNM buffer
(10 mM Tris pH 7.5, 10 mM NaCl, 1.5 mM MgCl2, 0.1%
Tween). After freeze-thawing, the viral proteins were analyzed
by SDS-PAGE or incubated with Glutathione sepharose 4B
beads (GE Healthcare life science) overnight at 4uC. The
GSH-beads were washed five times with TNM buffer and
boiled in 16 SDS-PAGE sample buffer and analyzed by
SDS-PAGE.
Confocal microscopy
Cells were grown to subconfluency in a 8-well chamber slide
(Lab-tek, II, Nunc, Germany) and infected with the appropriate
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virus at an MOI of 10. After 1 h, virus was removed and cells were
treated with TP219 (50 mM). After 5 h, cells were fixed with 4%
paraformaldehyde and permeabilized with PBS containing 0.5%
Saponin. Subsequently, cells were stained with primary and
fluorescently-labeled secondary antibodies. Nuclei were stained
with DAPI. Cells were visualized using a confocal laser scanning
microscope (LCSM, Leica Microsystems, Germany).
Supporting Information
Figure S1 TP219 has no effect on intracellular GSH
levels in HeLa cells. Effect of TP219 (white bars) and BSO
(grey bars) on intracellular reduced (GSH) levels in BGM cells,
expressed as percentage untreated control at various time points
post incubation.
(TIF)
Figure S2 HPLC chromatogram of a new conjugate.
TP219 and GEE were co-incubated for 6 h and analyzed by
HPLC. Samples were analyzed at two wavelengths l=254 nm (A)
and l=230 nm (B).
(TIF)
Figure S3 Cross-resistance to BSO. BSO inhibits formation
of infectious virus particles of wild-type (white bars) but not of
T77M (grey bars) CVB3 in a dose-dependent manner. Virus titers
were calculated by endpoint titration and expressed as tissue
culture 50% infectious dose per ml (Log10 TCID50/ml). Data are
average values 6 SD.
(TIF)
Figure S4 GSH depletion interferes with the interaction
of VP1 and 2C. BGM cells were infected with T77M/A180T
CVB3 at a MOI of 10, in the absence or the presence of 50 mM
TP219. Cells were fixed with saponin 0.5% at 5 h p.i. and
costained with antibodies targeting 2C (and Alexa Fluor 568-
conjugated secondary antibody (red color)) and VP1 (and Alexa
Fluor 488-conjugated secondary antibody (green color)). Regions
of colocalization are indicated by arrows.
(TIF)
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